With the disclosure of the annual report and the first quarterly report of domestic A-share listed companies drawing to a close, the positions of some companies in Gaoyao Capital have changed. 1. Gaochun Capital has continuously reduced its positions: Wuxi PharmaTech, small molecular CRO track.
Gaolin Capital directly invests in WuXi PharmaTech and Wuxi Bio through the primary market. The entity that Gaolin Capital invested in WuXi PharmaTech is an investment entity company registered in Hong Kong: HCFII WX(HK) Wuxi Hong Kong Holdings Co., Ltd. When WuXi PharmaTech went public in IPO, the prospectus had already disclosed the relationship between HCFII WX(HK) and Gaoyao Capital.
As a shareholder holding more than 5% of the shares, Gaoyan Capital has a lock-up period of one year. After the 1 year lifting of the ban, Gaoling Capital began to continuously reduce its holdings of Wuxi PharmaTech. As of 20 19, 12 and 3 1 day, Gaoying Capital held 47.95 million shares of the drug name Kant, accounting for 2.90%.
2. Gaoling Capital holds the Tiger Medicine CRO track unchanged.
Gao Yan Capital's secondary market QDII fund: HCM China Fund continues to hold 7.5 million shares of Tiger Pharmaceutical, accounting for 65,438+0.0% of the total share capital. Gao Yan Capital also holds Gloria Ying, Fangda Holdings and Gao Yan Capital have held Gloria Ying for at least 1.5 years, with relatively large holdings of more than 2 billion RMB, and their positions are not light. Fangda Holdings has not changed for the time being.
3. Gao Yan Capital continued to increase its position in Fang Shuijing (Shanghai: 600779).
Gao Yan Capital has a fund in the RMB secondary market: Tianjinliren Investment Management Partnership Fund, and the only company that has entered the top ten shareholders of A shares is the second high-end.
4. The shareholding ratio of Aier Ophthalmology, Gree Electric, Bull Group, Liangpin Shop and Conch remains unchanged.
Aier Ophthalmology, Gree Electric and Conch are all held by Gaochun Capital HCM China Fund, which is a secondary market fund. The shares of these three companies remain unchanged.